Since February 2022, the renowned engineering companies OTZ and JBJ have established a strategic partnership to engage in major projects within the Life Sciences sector, with an emphasis on the Pharmaceutical Industry.

The alliance between these two companies aims to combine their extensive experience and capacity to execute large-scale projects, enhancing the performance of both companies in the sector through this synergy.

Strength Through Experience

OTZ Engineering, renowned for its excellence in large industrial and infrastructure projects, and JBJ Engineering, a standout in the life sciences market with numerous projects and specialized consulting, have decided to join forces to explore the promising pharmaceuticals and life sciences market. By combining their resources, technical knowledge, and skills, the companies aim not only to expand their capabilities but also to offer more efficient and innovative solutions to the market.

"The partnership with JBJ Engineering represents another important milestone for OTZ, in terms of diversifying our areas of operation. Together, our teams can offer integrated and cutting-edge engineering solutions to the pharmaceutical industry, promoting advancements that will benefit the entire production chain," stated [Marcelo Pereira, CEO of OTZ Engineering].

In turn, JBJ Engineering highlights the complementarity of competencies as one of the main strengths of the collaboration. "OTZ's expertise in Large Multidisciplinary Projects perfectly complements our experience in process technologies and automation. We are excited about the opportunities this partnership brings us," commented [Jonas Beraldo, CEO of JBJ Engineering].

Significant Projects in the Pharmaceutical Industry

Both companies already have a track record of successful projects in the pharmaceutical industry. For instance, OTZ Engineering was responsible for the expansion projects of FarManguinhos and Bravet.

Meanwhile, JBJ Engineering led several important projects for the Butantan Institute, as listed below:

CENTRUM BIOTERIUM FACILITY AND RESEARCH LABORATORY (BSL2 AND BSL3)

SERUM PRODUCTION CENTER WITH STERILE PRODUCTION AND FILLING (LYOPHILIZED AND LIQUID)

HEPATITIS VACCINE PRODUCTION PLANT (BSL 2)

FINAL PROCESSING CENTER FOR IMMUNOBIOLOGICAL FORMULATION AND VACCINE FILLING - VIALS, SYRINGES, LYOPHILIZED AND LIQUID PRODUCTS (4 LINES -> 1 BSL2 LINE)

Benefits of the Partnership

The synergy promises to bring various benefits to the sector. Among the main positive points are:

• OTZ:

o   A team trained to manage, coordinate, plan, and monitor large-scale projects through proprietary methodology executed with a set of specific tools.

o   Professionals with extensive experience in all disciplines.

• JBJ:

o   Long-term experience in Life Sciences projects, especially in the pharmaceutical sector.

3. Sustainability: The partnership also focuses on sustainable solutions, aiming to reduce the environmental impact of implementing industrial operations.

4. Safety and Quality: The joint experience in large-scale projects ensures that new ventures will meet the highest standards of safety and quality, essential in the pharmaceutical industry.

Promising Future

The reached agreement is a clear demonstration of the companies' commitment to contributing to the development of the pharmaceuticals and life sciences sector. With a shared vision of innovation and excellence, the partnership is set to bring significant tangible benefits to society and the market.

The coming months promise intense collaboration and development, with both companies working on joint projects that will not only reinforce their market position but also propel the Brazilian pharmaceutical industry to new heights.